EGFR-TKI靶向治疗联合TC化疗方案治疗突变型非小细胞肺癌患者对肝肾功能指标的影响

摘要/Abstract

摘要： 目的探讨表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）靶向治疗联合TC化疗方案治疗突变型非小细胞肺癌患者对肝肾功能指标的影响。方法选取2017年6月—2019年6月富平县医院收治的100例突变型非小细胞肺癌患者作为研究对象进行回顾性分析,依照治疗方式将患者分为观察组与对照组,每组50例。对照组患者采取单一TC化疗方案治疗,观察组患者采取EGFR-TKI靶向治疗联合TC化疗方案治疗,对比两组患者临床疗效,生存情况以及治疗前后肝肾功能指标变化。结果观察组客观缓解率与疾病控制率明显高于对照组（P<0.05）;观察组中位无进展生存期（PFS）为11.26（2.38~24.13）,对照组中位PFS为9.25（2.24~17.22）,观察组高于对照组（χ²=4.536,P=0.041）,观察组中位总生存期（OS）为21.23（4.84~62.73）,对照组中位OS为16.52（5.27~50.27）,观察组高于对照组（χ²=5.262,P=0.022）;两组患者治疗前谷丙转氨酶（ALT）、谷草转氨酶（AST）、血肌酐（Scr）、尿素氮（BUN）对比,差异无统计学意义（P>0.05）,治疗后两组患者ALT、AST、SCr、BUN水平均升高,但观察组与对照组对比,差异无统计学意义（P>0.05）。结论 EGFR-TKI靶向治疗联合TC化疗方案治疗突变型非小细胞肺癌疗效显著,且能够提升患者无进展生存期和总生存期,而且与单一TC化疗方案治疗相比并不增加肝肾功能损伤程度。

关键词: 皮生长因子受体酪氨酸激酶抑制剂, 化疗, 突变型, 非小细胞肺癌, 肝功能, 肾功能

Abstract: Objective To investigate the effect of Targeted therapy of epidermal growth factor Receptor tyrosine kinase inhibitor (EGFR-TKI) combined with TC chemotherapy on liver and kidney function in patients with Mutant non-small cell lung cancer. Methods A total of 100 patients with mutant non-small cell lung cancer admitted to Fuping County Hospital from June 2017 to June 2019 were selected as the study subjects for retrospective analysis. According to the treatment methods, the patients were divided into an observation group and a control group, with 50 cases in each group. The patients in the control group were treated with a single TC chemotherapy scheme, and the patients in the observation group were treated with EGFR-TKI Targeted therapy combined with TC chemotherapy scheme. The clinical efficacy, survival and changes of liver and kidney function indexes before and after treatment of the patients in the two groups were compared. Results The Objective remission rate and disease control rate of the observation group were significantly higher than those of the control group (P<0.05); The median PFS of the observation group was 11.26 (2.38-24.13), the median progression-free survival (PFS) of the control group was 9.25 (2.24-17.22), which was higher in the observation group than in the control group (χ²=4.536, P=0.041), and the median overall survival (OS) of the observation group was 21.23 (4.84-62.73). The median OS of the control group was 16.52 (5.27-50.27), which was higher in the observation group than in the control group (χ²=5.262, P=0.022); Before treatment, the levels of alt, AST, SCR and BUN in the two groups had no significant difference (P>0.05). After treatment, the levels of alt, AST, SCR and BUN in the two groups increased, but there was no significant difference between the observation group and the control group (P>0.05).Conclusion EGFR-TKI Targeted therapy combined with TC chemotherapy regimen has a significant effect in the treatment of mutant non-small cell lung cancer, and can improve the progression free survival period and total survival period of patients, and does not increase the degree of liver and kidney function damage compared with the single TC chemotherapy regimen.

Key words: skin growth factor receptor tyrosine kinase inhibitor, chemotherapy, mutant, non small cell lung cancer, liver function, renal function

中图分类号:

R734.2

陈冲, 徐翠萍. EGFR-TKI靶向治疗联合TC化疗方案治疗突变型非小细胞肺癌患者对肝肾功能指标的影响[J]. 中华养生保健, 2024, 42(12): 166-169.

CHEN Chong, XU Cui-ping. Effect of EGFR-TKI Targeted Therapy Combined with TC Chemotherapy Regimen on Liver and Kidney Function in Patients with Mutant Non small Cell Lung Cancer[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(12): 166-169.

参考文献

[1] GENG Y, ZHANG Q, FENG S, et al.Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis[J]. Cancer Med,2021,10(4):1222-1239.
[2] JIANG J, WANG Y, GAO Y, et al.Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis[J]. Transl Lung Cancer Res,2022,11(2):277-294.
[3] 邢如月,李梦梦,张国伟,等.阿美替尼治疗EGFR突变晚期非小细胞肺癌疗效及安全性分析[J]. 肿瘤学杂志, 2022, 28(6): 472-478.
[4] 郝娟,周光华,陈忆玲.EGFR-TKI靶向联合放疗,化疗治疗Ⅳ期EGFR突变型非小细胞肺癌的临床效果[J].湖南师范大学学报:医学版,2021,18(2):109-112.
[5] 冯浩洁,姚颐,耿庆.美国国家综合癌症网络临床实践指南:非小细胞肺癌(2021V1)更新解读[J].临床外科杂志,2021,29(1):25-28.
[6] 张松松,赵云娇,牛玉莹,等.晚期癌症患者癌痛的规范化治疗疗效评估(附115例)[J].现代肿瘤医学,2019,27(17):3114-3117.
[7] 季刚,朱晓丽,张玲,等.BEAMingddPCR与SuperARMS检测EGFR酪氨酸激酶抑制剂治疗后非小细胞肺癌患者循环肿瘤DNAEGFR基因突变的比较研究[J].中国癌症杂志,2020,30(5):335-339.
[8] 张碧霞,丁江华.EGFR突变型非小细胞肺癌EGFR-TKI获得性耐药后免疫治疗现状[J].国际肿瘤学杂志,2023,50(2):97-101.
[9] 贾燕华,陈日新,李竟长,等.放疗同步EGFR-TKI治疗与先放疗后EGFR-TKI治疗在EGFR基因突变型非小细胞肺癌脑转移中的应用效果对比[J].广西医学,2022,44(6):585-589.
[10] 王皓,曾晨欣,李俐,等.奥希替尼和阿美替尼/厄洛替尼一线治疗EGFR突变阳性非小细胞肺癌的成本-效果分析[J].医药导报,2020,39(12):1689-1696.
[11] 李恩喜,达丽隽,祁雅丽,等.EGFR-TKI辅助治疗EGFR突变的非小细胞肺癌有效性和安全性的meta分析[J].重庆医学,2022,51(7):1195-1200.
[12] 王玲,杜倩宇,王西勇.安罗替尼联合化疗治疗驱动基因阴性晚期非小细胞肺癌的疗效及对血清VEGF、bFGF、MMP-9水平的影响[J].临床和实验医学杂志,2022,21(1):39-43.
[13] 徐静,何靓,钱慧珠,等.循环肿瘤细胞检测在EGFR合并TP53突变的晚期非小细胞肺癌一代EGFR-TKI治疗中的疗效评价[J].医学研究生学报,2022,35(3):278-282.
[14] 吴克林,吴天英.卡瑞利珠单抗联合化疗对老年非小细胞肺癌患者血清细胞角蛋白19片段抗原21-1、基质金属蛋白酶9表达及肿瘤生长转移的影响[J].实用医学杂志,2020,36(20):2830-2833.
[15] 张雪,胥莹,安文慧,等.五种评分系统判断TACE术治疗原发性肝癌患者发生肝功能不全效能比较研究[J].实用肝脏病杂志,2021,24(1):111-114.
[16] 杜晔,付鲁玉,郭一丹,等.原发性非小细胞肺癌患者PD-1/PD-L1抑制剂相关急性肾损伤的临床特征分析[J].临床肿瘤学杂志,2022,27(9):782-787.
[17] 左强,江国强,方芳,等.伏美替尼治疗EGFR突变阳性非小细胞肺癌EGFR-TKI耐药患者的临床观察[J].中国现代医学杂志,2022,32(14):30-34.